Brazil-based Bio-Manguinhos is working with the Bill & Melinda Gates Foundation to produce a combined measles and rubella vaccine for developing countries in Africa and other regions. GlaxoSmithKline ($GSK) transferred its MMR technology to Bio-Manguinhos in 2003, but cost and the limited incidence of mumps in some countries has limited uptake in Africa. The measles and rubella vaccine is intended to overcome these barriers. Article